CPZ

Across TCGA pan-cancer cohorts, CPZ mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CPZ data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CPZ mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CPZ expression acts as an unfavorable survival marker.

HNSC, PDAC, and LSCC are the cancer types where CPZ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.544	0.955	<.001	48	view →
PDAC	DFS	Quartile	All	0.657	0.907	.004	42	view →
LSCC	DFS	Median	II,III,IV	0.554	0.823	.024	8	view →
LUAD	OS	Quartile	II,III,IV	0.512	1.000	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CPZ–HNSC (OS)

Open the HNSC breakdown →